Design to come?

WP_Post Object
(
    [ID] => 881
    [post_author] => 3
    [post_date] => 2021-06-02 08:53:55
    [post_date_gmt] => 2021-06-02 13:53:55
    [post_content] => 
    [post_title] => Intensity Therapeutics’ INT230-6 Demonstrates Efficacy as Either Monotherapy or in Combination with Checkpoint Inhibitors in Patients with Relapsed, Refractory, Metastatic Solid Tumors
    [post_excerpt] => 
    [post_status] => publish
    [comment_status] => closed
    [ping_status] => closed
    [post_password] => 
    [post_name] => intensity-therapeutics-int230-6-demonstrates-efficacy-as-either-monotherapy-or-in-combination-with-checkpoint-inhibitors-in-patients-with-relapsed-refractory-metastatic-solid-tumors
    [to_ping] => 
    [pinged] => 
    [post_modified] => 2021-06-03 08:55:05
    [post_modified_gmt] => 2021-06-03 13:55:05
    [post_content_filtered] => 
    [post_parent] => 0
    [guid] => https://vcapital.com/?post_type=news&p=881
    [menu_order] => 0
    [post_type] => news
    [post_mime_type] => 
    [comment_count] => 0
    [filter] => raw
)